Staodyn
This article was originally published in The Gray Sheet
Executive Summary
Receives FDA permission to export its Dermapulse wound management system to The Netherlands. The company is setting up a European subsidiary, Staodyn BV, in The Netherlands which will market Dermapulse throughout the European Union ("The Gray Sheet" Nov. 29, p. 7). The firm also announces it will start shipping the device to Canada within 30 to 60 days, with European shipments "likely to start during the second half of 1994." Staodyn says it "continues to be optimistic" that FDA will approve its pending premarket approval application for Dermapulse, which it expects to be reviewed by an FDA panel this year
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.